Quick Answer 20/20 Biolabs, Inc. reported Operating Income of -$3.33 million for fiscal year 2025. 20/20 Biolabs, Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$3.33M +41.3% 2024 -$5.68M — 20/20 Biolabs, Inc. showed an increase of +41.3% in Operating Income compared to the prior fiscal year. Over the 2024–2025 … Read more
Quick Answer 20/20 Biolabs, Inc. reported Gross Profit of $604.5 thousand for fiscal year 2025. 20/20 Biolabs, Inc. Gross Profit — Annual History Fiscal Year Gross Profit YoY Change 2025 $604.5K +67.8% 2024 $360.3K — 20/20 Biolabs, Inc. showed an increase of +67.8% in Gross Profit compared to the prior fiscal year. Over the 2024–2025 … Read more
Quick Answer 20/20 Biolabs, Inc. reported R&D Expense of $592.6 thousand for fiscal year 2025. 20/20 Biolabs, Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $592.6K -53.0% 2024 $1.26M — 20/20 Biolabs, Inc. showed a decrease of -53.0% in R&D Expense compared to the prior fiscal year. Over the 2024–2025 … Read more
Quick Answer 20/20 Biolabs, Inc. reported Stockholders Equity of -$19.2 thousand for fiscal year 2025. 20/20 Biolabs, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 -$19.2K -101.3% 2024 $1.51M -64.9% 2023 $4.29M — 20/20 Biolabs, Inc. showed a decrease of -101.3% in Stockholders Equity compared to the prior fiscal year. … Read more
Quick Answer 20/20 Biolabs, Inc. reported Cash and Equivalents of $1.03 million for fiscal year 2025. 20/20 Biolabs, Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $1.03M -42.5% 2024 $1.78M — 20/20 Biolabs, Inc. showed a decrease of -42.5% in Cash and Equivalents compared to the prior fiscal … Read more
Quick Answer 20/20 Biolabs, Inc. reported Total Assets of $4.14 million for fiscal year 2025. 20/20 Biolabs, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $4.14M +15.4% 2024 $3.58M — 20/20 Biolabs, Inc. showed an increase of +15.4% in Total Assets compared to the prior fiscal year. Over the 2024–2025 … Read more
Quick Answer 20/20 Biolabs, Inc. reported Diluted EPS of $0.76 per share (loss) for fiscal year 2025. 20/20 Biolabs, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$0.76 +34.5% 2024 -$1.16 — 20/20 Biolabs, Inc. showed an increase of +34.5% in Diluted EPS compared to the prior fiscal year. Over … Read more
Quick Answer 20/20 Biolabs, Inc. reported Net Income of -$3.74 million for fiscal year 2025. 20/20 Biolabs, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$3.74M +32.7% 2024 -$5.55M — 20/20 Biolabs, Inc. showed an increase of +32.7% in Net Income compared to the prior fiscal year. Over the 2024–2025 … Read more
Quick Answer 20/20 Biolabs, Inc. reported Total Revenue of $2.05 million for fiscal year 2025. 20/20 Biolabs, Inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $2.05M +16.7% 2024 $1.75M — 20/20 Biolabs, Inc. showed an increase of +16.7% in Total Revenue compared to the prior fiscal year. Over the 2024–2025 … Read more
Quick Answer 20/20 Biolabs, Inc. reported Total Revenue of $2.05 million for fiscal year 2025. 20/20 Biolabs, Inc. — Key Financials by Year Metric 2025 2024 2023 Total Revenue $2.05M+16.7% $1.75M — Net Income -$3.74M+32.7% -$5.55M — Diluted EPS -$0.76+34.5% -$1.16 — Total Assets $4.14M+15.4% $3.58M — Cash and Equivalents $1.03M-42.5% $1.78M — Stockholders Equity … Read more